Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib long-term safety in CLL/SLL and NHL
NCT06876662Phase 4Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2025
- Primary completion
- May 2030
- Countries
- 8
01
Overview
Phase 4, open-label, single-arm trial of pirtobrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), sponsored by Eli Lilly and Company. Primary endpoint: Treatment-Emergent Adverse Events. Started May 2025; status: recruiting.
02
Drugs
pirtobrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06876662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06876662.